Melissa B. Epperly, Director at Roivant Sciences Ltd. (ROIV), sold 4,938 shares at $39.65 ($196K) on 2026-09-15, disclosed to the SEC on 2026-09-17.
Scheduled sale ($196k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $39.65 | 4,338 | $172K | 87.7% |
| 2 | $40.38 | 600 | $24K | 12.3% |
| Total | $39.74 avg | 4,938 | $196K | 100% |
| Filing → |
| ROIV | SELL | 2026-03-18 | $1.2M | — | Filing → |
| ZNTL | SELL | 2024-02-12 | $29K | — | Filing → |
| ZNTL | SELL | 2024-02-05 | $200K | — | Filing → |